Methyl jasmonate and its potential in cancer therapy.

Methyl jasmonate (MeJa) is a naturally occurring hydrophobic oxylipin phytohormone. Early findings obtained from cancer cell lines suggest that MeJa is endowed with anticancer capabilities. It has been recently proposed that MeJa represents a novel agent that exhibits direct and selective actions against tumor cells without affecting normal human cells. In a previous study, I reported that MeJa itself is enough to result in the dysfunction of mitochondria and chloroplasts, as well as to activate cell death program (apoptosis), in the normal protoplasts of Arabidopsis thaliana. Indeed, this also holds true for other living plant systems in which senescence, hypersensitive response and oxidative stress have been found under MeJa action. Therefore, in this addendum to my previous article, I would like to stress that much more attention should be paid to the potential effect(s) of MeJa, or its derivatives, on healthy cells and tissues before it is used for clinical anticancer drugs, whether being used alone or in combination with other agents.